Talha Badar: TKI Selection Based on Mutation Profiles in CML at EHA 2025

Talha Badar, Hematology/Oncology Specialist at Mayo Clinic, shared a post on X:

“Emergence of ASXL1 and tyrosine kinase domain mutation with different TKI; imatinib, 2nd generation TKI and asciminib. Best choice of TKI with respect to mutation.”